Corona Remedies Ltd Q1 FY27 Earnings Call: Beats 15% Revenue Guidance, EBITDA Margin Expands to 22%

Corona Remedies Ltd held its Q1 FY27 earnings call on July 31, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline performance beats guidance across all metrics

• Revenue of Rs.422 Cr — grew 21.9% YoY in Q1 FY 2026-2027, well above the 15% full-year guidance; India business contributed 97% of total revenue and grew 22.7% YoY.
• EBITDA of Rs.93 Cr — margin expanded 190 bps to 22% in Q1 FY 2026-2027, driven by favorable product mix and operating leverage.
• PAT of Rs.60 Cr — increased 30.1% YoY; PAT margin widened 90 bps to 14.2% in Q1 FY 2026-2027.
• Organic growth of 21.4% — excluding the acquired Vocadin portfolio; 85% of Q1 revenue growth came from organic business, only 15% from brands acquired 3-4 years ago.
• Chronic and semi-chronic therapies — constituted 73.4% of the total portfolio in Q1 FY 2026-2027, reinforcing the shift toward high-margin, recurring revenue.

Women's health and urology lead; brand ladder scaling rapidly

• Women's healthcare grew 23.3% — 2.5x the IPM growth rate; Corona ranks #5 in women's healthcare and #5 in pain management within the IPM.
• Urology grew 27.6% — vs. IPM growth of 40.9% in the category; Corona ranks #9 in urology within the IPM.
• Cardio-diabeto outperformed by 1.7x — ranked #20 in IPM but top 10 in the consolidation business; therapy growing at ~15% (IPM), management plans to maintain top-10 momentum.
• Pain management outperformed by 1.54x — strong relative performance vs. the IPM benchmark.
• Brand portfolio scaling — brands with annual revenue >Rs.100 Cr increased from 1 to 2; brands >Rs.10 Cr grew from 32 to >40; two new brands entered the Rs.10 Cr club in Q1 FY 2026-2027, both organic launches.
• Per PharmaTrack data for May-June 2026 — volume growth stood 6.3% (vs. IPM 12.3%), new introductions contributed 3.4% (vs. IPM 2.9%), and price-led growth was 8.7% (vs. IPM 5.6%).

FY27 targets reaffirmed; GLP-1 and IVF provide long-term optionality

• FY 2026-2027 guidance unchanged — 15% organic revenue growth, ~2% inorganic (Vocadin-driven), total ~17% revenue growth, and 20% PAT growth; management expects to beat IPM by 500 bps.
• IPM expected to grow 9-11% — management expects double-digit IPM growth in FY 2026-2027 and beyond, driven by post-COVID normalization and a return to historical trends.
• Vocadin brand target — management targets doubling the brand from Rs.20 Cr (internal revenue in FY 2025-2026) to Rs.40 Cr over three years; Q1 FY 2026-2027 was a transition quarter for supply chain integration.
• Semaglutide ambition — management expects the GLP-1 market to reach Rs.1,500-1,800 Cr and aims for a top 10 position in the semaglutide segment.
• IVF business launched April 2026 — revenue has started but it is too early to comment; management expects to provide more clarity in 2-3 quarters.
• Bayer Zydus portfolio (No-Clot brand) — generated Rs.7 Cr in revenue in Q1 FY 2026-2027, fully recovering the Rs.7 Cr acquisition cost in the first quarter.

EU GMP-approved plant commissioned; export revenue expected from FY29

• New EU GMP-approved hormone facility — commissioned on 30 June 2026 (end of Q1 FY 2026-2027); total capex of Rs.130 Cr; all pre-commercialisation costs capitalised, so no material P&L impact yet.
• Turnover ratio <1 in FY 2026-2027 — expected to improve to 2-3 over the next three years; domestic market will drive the initial ramp-up.
• International timeline — dossiers expected by November-December 2026; approvals and initial international business anticipated in 12-18 months, with export revenue projected to commence in FY 2028-2029.
• La Chandra Pharma Labs (31% stake) — API manufacturer with EU GMP and US DMF approvals; produces ~65% of India's progesterone; captive consumption estimated at 60-65% of Corona's total hormonal API requirement.
• International share remains modest — management stated "international business is projected to remain at a higher single-digit share even after 5 years (by FY31-32)"; >90% of business expected to stay domestic.

Operating leverage drives margin expansion; raw material headwind expected in Q2

• EBITDA margin improved 190 bps to 22% — driven by favorable product mix and operating leverage in Q1 FY 2026-2027; management is cautious about sustaining current levels due to geopolitical Southeast Asia risk but aims to maintain a similar range.
• Raw material headwind of ~100 bps expected — in Q2 FY 2026-2027 from geopolitical disturbances; management aims to maintain the 20% PAT growth guidance for FY 2026-2027 through operating cost reductions.
• Employee costs elevated — due to a 35% increase in medical reps to 3,111 over the ~3.5 years preceding Q1 FY 2026-2027; operating leverage is expected to reduce this cost as a percentage of revenue in future periods.
• Other expenses at ~30% of revenue — primarily sales promotion costs governed by UCPMP guidelines and are variable; management expects a lower percentage trajectory over the medium term.
• Depreciation & amortisation rose to Rs.13.4 Cr — from Rs.10 Cr in Q1 FY 2025-2026, driven by Vocadin (Rs.10 Cr annual, amortised over 10 years) and Bayer brand amortisation; additional depreciation expected from hormonal block capitalisation (Rs.130 Cr capex, depreciated over 20 years at Rs.6.5 Cr annual).
• In-house manufacturing at 60% — expected to remain at 60:40 (in-house vs. outsourced) for FY 2026-2027; no new MRs added in FY 2026-2027 (400 reps added in Q4 FY 2025-2026); long-term annual MR addition guidance is 6-8% (200-250 reps per year).